1. Home
  2. MGN vs INBS Comparison

MGN vs INBS Comparison

Compare MGN & INBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MGN

Megan Holdings Limited Ordinary Shares

HOLD

Current Price

$0.14

Market Cap

5.8M

Sector

N/A

ML Signal

HOLD

INBS

Intelligent Bio Solutions Inc.

HOLD

Current Price

$2.55

Market Cap

5.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MGN
INBS
Founded
2020
2016
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.8M
5.7M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
MGN
INBS
Price
$0.14
$2.55
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.4M
172.8K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
68.65
EPS
N/A
N/A
Revenue
N/A
$1,980,484.00
Revenue This Year
N/A
$778.48
Revenue Next Year
N/A
N/A
P/E Ratio
$32.33
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.13
$0.54
52 Week High
$5.18
$24.90

Technical Indicators

Market Signals
Indicator
MGN
INBS
Relative Strength Index (RSI) 32.31 42.69
Support Level $0.13 $2.33
Resistance Level $0.20 $3.16
Average True Range (ATR) 0.02 0.52
MACD 0.04 -0.07
Stochastic Oscillator 15.90 6.78

Price Performance

Historical Comparison
MGN
INBS

About MGN Megan Holdings Limited Ordinary Shares

Megan Holdings Ltd is principally engaged in the development, construction and maintenance of aquaculture farms and related works. Its operations are based in Malaysia. The company's operating segments include: Aquaculture and agriculture; Industrial solutions; and Investment in marketable securities. It derives maximum revenue from Aquaculture and agriculture, which involves development, construction, and maintenance of aquaculture and agriculture farms and related works.

About INBS Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.

Share on Social Networks: